This site is intended for Healthcare professionals.
×

Indian Immunologicals invests Rs 75 crore to set up new Sterile Filling Facility in Telangana

................................ Advertisement ................................


business medical dialogues

With this investment of Rs 75 crores in the upcoming filling facility, Indian Immunologicals Limited expects to increase its capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab.

New Delhi: Biologicals firm Indian Immunologicals Ltd. (IIL) has recently announced the ground-breaking of a new Sterile Filling Facility (SFF) at its manufacturing plant in Phase III of Genome Valley, Karkapatla, Ranga Reddy District, Telangana.

With this investment of Rs 75 crores in the upcoming filling facility, Indian Immunologicals Limited expects to increase its capacity to supply lifesaving vaccines such as the Anti Rabies Vaccine (ARV) – Abhayrab.

................................ Advertisement ................................

The new state-of-the-art facility expected to be ready later next year. The sterile facility is equipped with hi-end filling equipment from the world’s best manufacturers, in line with the requirements of the nature of work handled at the plant.

................................ Advertisement ................................

Commenting on the same, Dr K. Anand Kumar, Managing Director – Indian Immunologicals Limited said, “IIL has a long history of supplying vaccines critical to public health. We are constantly striving to make the vaccines affordable and accessible to reach the benefits of preventive healthcare to the maximum number of people. The expansion at Karkapatla plant is in line with our mission and will help meet the growing requirements of critical vaccines”.

Various reports in the past few months indicate that several states in the country have reported shortages of ARV, due to a combination of factors including growing demand, imperfect demand signal, and supply disruptions. Reports indicate that the shortages sometimes extend to the tune of 60-80%.

“Currently there are reports of shortages of anti-rabies vaccine in the country. Investment in a new sterile filling facility shows that IIL is committed to expanding manufacturing capacity to meet unmet public health needs in India. With supply from this facility, IIL will continue to be the largest rabies vaccine manufacturer in the country,” added Dr Prasanna Deshpande, Deputy Managing Director, Indian Immunologicals Limited.

................................ Advertisement ................................

IIL has 4 manufacturing facilities at various locations – Karkapatla, Telangana – Human Vaccines & Animal Health Formulations; Ooty, Tamil Nadu – Anti Rabies production unit; Hyderabad, Telangana – Human Biologicals Unit (Gachibowli) and animal vaccines unit; Dargaville, New Zealand – New Bovine Serum. IIL exports various Human and animal vaccines to over 50 countries and currently employs around 1,300 people.

Also Read: SMT to set up Rs 250-crore stent unit in Telangana

Spread the love

Author Details

Farhat Nasim

Farhat Nasim joined Medical Dialogues an Editor for the Business Section in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier’s College Ranchi. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

To know about our editorial team click here

Source: self
0 comment(s) on Indian Immunologicals invests Rs 75 crore to set up new Sterile Filling Facility in Telangana

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted

    ................................ Advertisement ................................